NIKI

Niki BioSolutions Inc

1.77

Oct 30 • 3:59 PM ET -0.19 (-9.51%)

1.70

Aftermarket • 7:30 PM ET -0.07 (-3.95%)

Healthcare Biotechnology USA Nano NASD

Peers: ACXP PCSA ARMP SPRO ANTX AIM KZIA IVVD SCYX CPIX

Scroll to Statements

Index	-
Market Cap	5.52M
Enterprise Value	-3.78M
Income	-
Sales	-
Book/sh	28.38
Cash/sh	1.11
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	2
IPO	Dec 18, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.06
P/C	1.60
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.78
Current Ratio	0.78
Debt/Eq	0.15
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	59.28% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-1980.90%
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	-
Insider Trans	-
Inst Own	1.16%
Inst Trans	-42.83%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-34.39%
SMA50	-61.75%
SMA200	-77.06%
Trades

Shs Outstand	0.63M
Shs Float	-
Short Float	-
Short Ratio	0.06
Short Interest	0.01M
52W High	17.20 -89.71%
52W Low	1.78 -0.56%
Volatility	11.87% 13.60%
ATR (14)	0.37
RSI (14)	20.92
Beta	0.19
Rel Volume	0.10
Avg Volume	97.33K
Volume	9,996

Perf Week	-3.28%
Perf Month	-63.20%
Perf Quarter	-81.50%
Perf Half Y	-79.89%
Perf YTD	-83.30%
Perf Year	-87.96%
Perf 3Y	-89.59%
Perf 5Y	-99.27%
Perf 10Y	-
Recom	-
Target Price	230.00
Prev Close	1.96
Price	1.77
Change %	-9.51%

Oct-26-26 09:15AM	Niki BioSolutions Announces New York State Approval for Its APOE Genotyping Test Using Dried Blood Spots, Plasma, and Urine (GlobeNewswire)
Oct-23-26 08:00AM	Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research (GlobeNewswire)
Oct-16-26 08:00AM	Niki BioSolutions' Rett Syndrome Biomarker Program Featured in the International Rett Syndrome Foundation's "Rett Research Tool Belt" Series (GlobeNewswire) -8.56%
Oct-14-26 08:00AM	Niki BioSolutions Partners with Global Alzheimer's Platform Foundation to Deliver Plasma-Based APOE Genotyping for Bio-Hermes-002 (GlobeNewswire) -18.28%
Sep-25-26 08:30AM	Niki BioSolutions to Participate in the Lytham Partners Fall 2026 Investor Conference (GlobeNewswire)
08:30AM	Loading…
Sep-14-26 08:30AM	Niki BioSolutions Accelerates Its Alzheimer's Disease Testing Pipeline Through Strategic Bioinformatics and Statistical Analysis Partnership with Fios Genomics (GlobeNewswire)
Sep-08-26 08:00AM	Niki BioSolutions to Participate in H.C. Wainwright's 28th Annual Global Investment Conference (GlobeNewswire)
Jul-16-26 11:00AM	Aptorum Group Provides Update on DiamiR Biosciences Merger (GlobeNewswire) -15.34%
Jul-08-26 08:00AM	Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer's Association International Conference (GlobeNewswire)
Jun-22-26 08:00AM	Aptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer's Disease Biomarkers (GlobeNewswire)
Jun-10-26 08:00AM	Aptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR Biosciences (GlobeNewswire) -19.30%
Apr-15-26 10:00AM	THE Mining Investment Event 2026 Announces Keynote Speakers and Panels, Additional Sponsors and Participating Companies (TMX Newsfile) +7.82%
Apr-14-26 07:00AM	Andean Precious Metals Appoints Victor Flores as Senior Vice President, Exploration, Operations and Growth (TMX Newsfile)
Apr-08-26 07:00AM	Andean Precious Metals Reports Strong First Quarter 2026 Production Results (TMX Newsfile)
Mar-27-26 06:00AM	Andean Advises of Senior Management Change (TMX Newsfile) -8.82%
06:00AM	Loading…
Mar-25-26 06:00AM	Andean Precious Metals Reports Fourth Quarter and Year-End 2025 Financial Results (TMX Newsfile)
Mar-18-26 07:00AM	Andean Precious Metals Announces Inclusion in VanEck Junior Gold Miners ETF (GDXJ) (TMX Newsfile)
Mar-10-26 08:00AM	Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania (GlobeNewswire)
Mar-06-26 04:30PM	Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire)
Feb-02-26 08:00AM	Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB's Automated APOE Testing Platform for Alzheimer's Disease (GlobeNewswire) -10.22%
Nov-19-25 08:00AM	DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference (GlobeNewswire)
Oct-10-25 09:54AM	Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering (GlobeNewswire) -29.96%
Oct-09-25 08:55AM	As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executives (GlobeNewswire)
Sep-05-25 08:00AM	Aptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-21-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +234.65%
07:07AM	DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR's APOE Genotyping Test (GlobeNewswire)
Aug-04-25 08:15AM	Aptorum Group Limited Regains Compliance with NASDAQ's Minimum Bid Price Requirement (GlobeNewswire)
Jul-16-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +100.04%
08:38AM	Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement (GlobeNewswire)
Apr-16-25 12:27PM	Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire) -15.28%
06:28AM	Loading…
Jan-08-25 06:28AM	Aptorum Group to Issue 1.5 Million Class A Shares (TipRanks) -10.62%
Jan-02-25 10:55AM	Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering (GlobeNewswire) -21.43%
Dec-31-24 10:17AM	Why Aptorum Group (APM) Jumped Nearly 300% at Pre-Market Trading (Insider Monkey) +106.64%
Dec-20-24 04:00PM	Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024 (Business Wire)
Apr-30-24 09:15AM	Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update (Business Wire) +7.58%
Apr-12-24 06:40AM	7 A-Rated Aggressive Biotech Stocks to Bet On in 2024 (InvestorPlace)
Mar-06-24 08:00AM	Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business (Business Wire) +554.44%
Dec-22-23 04:30PM	Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023 (Business Wire) +10.95%
Dec-21-23 04:30PM	Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders (Business Wire) +8.96%
Nov-16-23 11:00AM	Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023 (Business Wire)
Aug-10-23 02:57AM	Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets (Business Wire)
Aug-05-23 02:53PM	10 Oversold Global Stocks To Buy (Insider Monkey)
Jun-22-23 08:00AM	Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma (Business Wire)
Jun-09-23 04:30PM	Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris (Business Wire)
May-05-23 04:31PM	Aptorum Group Receives Nasdaq Notification of Minimum Stockholders Equity Deficiency (Business Wire) +11.23% -31.96%
May-01-23 08:00AM	Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Groups Subsidiary Paths Innovations Limited (Business Wire) +5.53%
06:10AM	Aptorum Group Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Apr-28-23 09:44AM	Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update (Business Wire) -10.92%
Mar-27-23 07:00AM	Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group (Business Wire) +9.66%
Mar-17-23 08:15AM	Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R) (ACCESSWIRE)
Mar-03-23 07:30AM	Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus (Business Wire)
07:30AM	Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma (Business Wire)
Mar-02-23 07:30AM	Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China (Business Wire) +10.12%
Feb-10-23 04:30PM	Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency (Business Wire) -6.25% +7.78%
Feb-06-23 10:08AM	Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023 (Business Wire) -11.54%
Jan-23-23 06:49AM	Owning 74% in Aptorum Group Limited (NASDAQ:APM) means that insiders are heavily invested in the company's future (Simply Wall St.)
Jan-20-23 08:00AM	Aptorum Group Announces 1-for-10 Reverse Stock Split (Business Wire)
Jan-04-23 09:00AM	Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms (Business Wire) +7.82%
Dec-22-22 08:00AM	Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders (Business Wire) +7.31%
Dec-16-22 08:00AM	Aptorum Group Announces Completion of $3 Million Convertible Note due 2023 (Business Wire) +6.38%
Dec-09-22 07:00AM	Aptorum Group Announces Offering of $3 Million Convertible Note due 2023 (Business Wire)
Nov-25-22 08:30AM	Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) (ACCESSWIRE)
08:00AM	Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG) (Business Wire)
Nov-18-22 05:30PM	Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency (Business Wire)
Nov-08-22 06:00AM	Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022 (Business Wire) +5.89%
Oct-07-22 03:40PM	HC Wainwright Initiates Aptorum On Upcoming "Innovative Pipeline" (Benzinga)
Sep-30-22 07:42PM	Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022 (Business Wire) -7.26%
Sep-23-22 08:00AM	Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) (ACCESSWIRE)
Sep-15-22 11:58AM	Aptorum Highlights Updates On Clinical Validation of RPIDD Infectious Disease Molecular Diagnostics (Benzinga) +5.52%
08:07AM	Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong (Business Wire)
07:00AM	Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics (Business Wire)
Sep-02-22 06:45AM	7 Hot Small-Cap Stocks to Buy in September (InvestorPlace) -6.21%
Aug-25-22 08:31PM	Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022 (Business Wire) -7.79%
Aug-19-22 08:30AM	Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) (ACCESSWIRE) -5.49%
Aug-11-22 09:45AM	Aptorum Group (NASDAQ:APM) shareholders are up 12% this past week, but still in the red over the last three years (Simply Wall St.)
May-17-22 08:13AM	Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 26 2022 (Business Wire) +5.71%
May-09-22 11:41AM	Here's Why We're Watching Aptorum Group's (NASDAQ:APM) Cash Burn Situation (Simply Wall St.)
May-02-22 08:00AM	Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma (Business Wire)
Apr-29-22 04:00PM	Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update (Business Wire)
Apr-25-22 09:30AM	First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted (Business Wire) -9.86%
Apr-22-22 08:00AM	Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report® (Business Wire)
Apr-06-22 07:00AM	Andean Precious Metals Announces RSU Grant (Newsfile)
Mar-22-22 05:58PM	Is Andean Precious Metals Corp.'s (CVE:APM) 4.2% ROE Worse Than Average? (Simply Wall St.) -9.27%
Mar-17-22 07:00AM	Andean Precious Metals Reports 2021 Earnings; Delivers on Silver Production and Cost Guidance (Newsfile)
Jan-25-22 10:06AM	SDC Stock Alert: What Has SmileDirectClub Investors Grinning Ear to Ear Today (InvestorPlace) +38.89%
08:21AM	APM Stock Alert: What Is Going on With Little-Known Aptorum Today? (InvestorPlace)
07:45AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jan-20-22 08:47AM	Aptorum Shares Rise After FDA Orphan Drug Tag For Repurposed Compound For Pediatric Cancer (Benzinga) +38.52%
08:00AM	Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma (Business Wire)
Jan-18-22 08:00AM	Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma (Business Wire)
Jan-11-22 04:56AM	Aptorum Group (NASDAQ:APM) investors are sitting on a loss of 90% if they invested three years ago (Simply Wall St.)
Jan-10-22 08:00AM	Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology (Business Wire)
08:00AM	Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers (Business Wire)
08:00AM	Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma (Business Wire)
Dec-03-21 08:00AM	Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders (Business Wire)
Oct-19-21 08:00AM	Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021 (Business Wire) -5.30%
Oct-15-21 08:00AM	Aptorum Group Limited Interview to Air on Bloomberg U.S. (Business Wire)
Sep-15-21 09:26AM	Aptorum To Start Testing SACT-1 In Neuroblastoma Patients (Benzinga) +5.32%
08:00AM	Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2021 (Business Wire)
08:00AM	Aptorum Group Limited Has Received IND Clearance From the US FDA to Initiate Clinical Trials for Repurposed Small Molecule Drug SACT-1 for the Treatment of Neuroblastoma (Business Wire)

Show Previous News

Niki Biosolutions, Inc. is a nonprofit organization company, focused on cancer prevention, HIV/AIDS awareness and treatment support. The company is headquartered in Princeton, NJ.

Head of FinanceMr. Kwok Kuen Wong

Ph.D.Dr. Alidad Mireskandari M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NIKI

Niki BioSolutions Inc

Upgrade your Finviz experience